Optic Neuropathy Management Market Snapshot (2023 to 2033)

The global optic neuropathy management market is expected to garner a market value of US$ 4.3 Billion in 2023 and is expected to accumulate a market value of US$ 7 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Optic Neuropathy Management registered a CAGR of 3.2% in the historical period 2018 to 2022.

The optic neuropathy management market is a segment of the healthcare industry that is focused on developing and distributing medical products and services for the treatment and management of optic neuropathy. Optic neuropathy is a condition that affects the optic nerve, which is responsible for transmitting visual information from the eyes to the brain. This condition can result in vision loss, blurred vision, and other symptoms.

The optic neuropathy management market includes a variety of products and services, including medications, surgical procedures, and diagnostic tools. Some of the key players in this market include pharmaceutical companies, medical device manufacturers, and healthcare providers.

Report Attribute Details
Expected Market Value (2023) US$ 4.3 billion
Anticipated Forecast Value (2033) US$ 7 billion
Projected Growth Rate (2023 to 2033) 5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Optic Neuropathy Management Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for optic neuropathy management reflected a value CAGR of 3.2% during the historical period, 2018 to 2022. One of the major drivers of the optic neuropathy management market is the increasing prevalence of optic neuropathy, which is associated with a range of underlying medical conditions, including diabetes, multiple sclerosis, and glaucoma. Additionally, the aging population is also contributing to the growth of this market, as the risk of developing optic neuropathy increases with age.

Advancements in technology and research are leading to the development of new diagnostic tools and treatment options. For example, the development of gene therapy and other innovative treatments may provide new options for managing optic neuropathy. Additionally, the use of advanced imaging techniques such as optical coherence tomography (OCT) is enabling earlier diagnosis and more precise monitoring of optic neuropathy, which could lead to better outcomes for patients.

Furthermore, increasing awareness and education about optic neuropathy among patients and healthcare providers is also contributing to market growth. As more people become aware of the condition and its impact on vision, there is likely to be increased demand for early diagnosis and effective treatment. The market for optic neuropathy management is expected to register a CAGR of 5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Optic Neuropathy Management Market?

Increasing Prevalence of Optic Neuropathy to push market growth

The increasing prevalence of optic neuropathy is expected to be one of the key drivers of market growth in the optic neuropathy management market. Optic neuropathy is a condition that affects the optic nerve, which transmits visual information from the eyes to the brain. The condition can result in vision loss, blurred vision, and other symptoms, and is associated with a range of underlying medical conditions, including diabetes, multiple sclerosis, and glaucoma.

The global prevalence of optic neuropathy is increasing, with estimates suggesting that the condition affects around 3% of the world's population. This is driving demand for new and innovative treatment options, as well as increasing the number of patients seeking care for the condition.

The rising incidence of underlying medical conditions such as diabetes and glaucoma is one of the main drivers of the increasing prevalence of optic neuropathy. Diabetes, for example, is a major risk factor for optic neuropathy, with diabetic retinopathy being a common cause of the condition. As the incidence of diabetes continues to rise globally, so too does the incidence of optic neuropathy.

Similarly, the incidence of glaucoma, which is another major cause of optic neuropathy, is also on the rise. Glaucoma is a group of eye diseases that can lead to damage of the optic nerve and is one of the leading causes of blindness worldwide.

Overall, the increasing prevalence of optic neuropathy is expected to drive significant growth in the optic neuropathy management market in the coming years. This presents opportunities for healthcare companies and providers to develop new and innovative solutions for managing the condition, as well as improving access to existing treatments and services.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Optic Neuropathy Management Market?

Expensive Cost of Treatment to restrict Market Growth

Despite advances in research and technology, there are still limited treatment options available for optic neuropathy. Many existing treatments focus on managing symptoms rather than addressing the underlying causes of the condition.

Optic neuropathy management can be costly, particularly for patients who require ongoing treatment and monitoring. This can make it difficult for patients to access the care they need, particularly in low- and middle-income countries.

Overall, addressing these challenges will be crucial to improving outcomes for patients with optic neuropathy and driving growth in the optic neuropathy management market. This will require a collaborative effort from healthcare providers, researchers, and policymakers to improve access to care, increase awareness and understanding of the condition, and develop new and innovative treatments and diagnostic tools.

Region-Wise Insights

How is the Optic Neuropathy Management Market Turning Out in the South & East Asia Region?

Increasing awareness and diagnosis of the condition Shaping Landscape for Optic Neuropathy Management in South & East Asia

The optic neuropathy management market in the South & East Asia region is growing, driven by increasing prevalence of underlying medical conditions such as diabetes, glaucoma, and hypertension, which are the leading causes of optic neuropathy in the region. The market is also being fueled by the growing aging population and rising awareness about the condition and its management among healthcare providers and patients.

In addition, there is a growing trend towards the adoption of advanced technologies and treatments for optic neuropathy management in the region. This includes the use of advanced imaging techniques such as optical coherence tomography (OCT) and electroretinography (ERG) to improve diagnosis and monitoring of the condition.

However, the market also faces several challenges in the South & East Asia region. One of the main challenges is limited access to healthcare and diagnostic services, particularly in rural areas. This can lead to delays in diagnosis and treatment, which can result in further vision loss and other complications.

Another challenge is the high cost of treatments, which can make it difficult for many patients to access the care they need. This is particularly true in low- and middle-income countries, where access to healthcare is limited and the burden of chronic diseases such as diabetes is high.

Overall, the optic neuropathy management market in the South & East Asia region is expected to continue to grow in the coming years, driven by a range of factors including increasing prevalence of the condition and the adoption of advanced technologies and treatments. However, addressing the challenges facing the market will be crucial to improving outcomes for patients and ensuring sustainable growth in the region.

What are the Factors Boosting the Market for Optic Neuropathy Management in North America?

Increasing Focus on Technological Advancements Shaping Landscape for Optic Neuropathy Management in North America

The optic neuropathy management market in North America is expected to experience significant growth in the coming years, driven by several factors. One of the primary drivers of market growth is the high prevalence of underlying medical conditions that can lead to optic neuropathy, such as diabetes, multiple sclerosis, and glaucoma. These conditions are becoming increasingly common in North America, particularly among the aging population, and are contributing to a growing demand for innovative and effective treatments for optic neuropathy.

In addition to the increasing prevalence of underlying medical conditions, the market is also being fuelled by advances in technology and research. New diagnostic tools and treatment options are being developed, including gene therapies, stem cell therapies, and neuroprotective agents, which are expected to improve outcomes for patients with optic neuropathy.

Another key factor driving the optic neuropathy management market in North America is the high level of awareness and understanding of the condition among healthcare providers and the general public. This has led to increased diagnosis rates and better management of the condition, which is contributing to improved patient outcomes.

Finally, the presence of well-established healthcare infrastructure and a high level of investment in research and development in North America are also expected to boost market growth. This has created a favorable environment for the development and commercialization of new and innovative products and treatments for optic neuropathy.

Overall, the optic neuropathy management market in North America is poised for significant growth in the coming years, driven by a range of factors including increasing prevalence of underlying medical conditions, advances in technology and research, high levels of awareness and understanding, and a favorable healthcare infrastructure and investment environment. As per FMI, the North America market is slated to hold a revenue share of 40%.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Route of Administration, Which Segment is Likely to Account for a Significant Share?

Injectable route of administration to hold a significant share and push market growth

The injectable route of administration is likely to account for a significant share of the optic neuropathy management market. This is due to the effectiveness of parenteral treatments, which can be administered directly into the bloodstream or affected area for faster and more targeted delivery of medication.

Injectable treatments are also preferred in cases where oral medications may not be suitable, such as for patients with difficulty swallowing or those who require higher doses that may not be feasible with oral medications. In addition, several established parenteral treatments for optic neuropathy are already available on the market, which further contributes to the dominance of the injectable segment.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies segment to hold a significant share and push market growth

Hospitals and specialty clinics are often the first point of contact for patients with optic neuropathy, as they provide specialized care and access to diagnostic tools and treatments. These facilities also have the expertise and resources to provide comprehensive care to patients with complex or severe cases of optic neuropathy.

In addition, many of the treatments for optic neuropathy require specialized administration or monitoring, such as intravitreal injections or electroretinography testing, which are typically performed in hospitals or specialty clinics. This further contributes to the dominance of these distribution channels in the optic neuropathy management market.

Overall, hospitals and specialty clinics are likely to continue to account for a significant share of the optic neuropathy management market, driven by the specialized care and expertise they provide. However, as patient preferences and healthcare delivery models continue to evolve, the market share of the various distribution channels may shift over time.

Market Competition

Key players in the market include companies such as AbbVie Inc., Eli Lily Company, GlaxoSmithKline, Pfizer Inc., Teva Pharmaceuticals, Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi A.S., Bristol-Myers Squibb and Company, along with healthcare providers and technology companies among other global players.

  • In March 2023, Horizon Therapeutics plc released the findings of a study analyzing the real-world use of teprotumumab-trbw (Tepezza, Horizon Therapeutics) in treating Thyroid Eye Disease (TED) patients with dysthyroid optic neuropathy (DON).
  • The study included a majority of patients who had previously not responded to other treatments. DON is a complication of TED that can result in vision loss due to the impairment of visual function caused by thyroid-related optic nerve compression. Teprotumumab-trbw is the only FDA-approved medication for treating TED, which is a rare autoimmune disease that is serious, progressive, and potentially vision-threatening.

Report Scope

Report Attribute Details
Market Value in 2023 USD 4.3 Billion
Market Value in 2033 USD 7 Billion
Growth Rate CAGR of 5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered Route of Administration, Distribution Channel, Drug Class, Region
Regions Covered North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa
Key Countries Profiled United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled AbbVie Inc.; Eli Lilly and Company; GSK Plc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; F. Hoffmann-La Roche AG; Bayer AG; Sanofi S.A; Bristol-Myers Squibb Company
Customization Available Upon Request

Key Segments Profiled in the Optic Neuropathy Management Industry Survey

Drug Class:

  • Corticosteroids
  • Antimetabolites
  • Anticoagulants
  • Serotonin and Norepinephrine Reuptake Inhibitors
  • Nonsteroidal Anti-Inflammatory Drugs

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Total Valuation of Current Optic Neuropathy Management Market?

The global market value is estimated to be near US$ 4.3 billion in 2023.

Which is the Favored Route of Administration for the Overall Optic Neuropathy Management Market?

The injectable route of administration is expected to remain the preferred choice during the forecast years.

What is the Share of North America in the Global Optic Neuropathy Management Market?

A higher prevalence of underlying medical conditions makes North America the leading market.

What is the Contribution of South & East Asia in the Global Optic Neuropathy Management Market?

The regional markets in South & East Asia are expected to follow a higher growth rate through 2033.

Which is the Bigger Challenge for the Expansion of the Optic Neuropathy Management Providers?

The availability of limited treatment options remains a significant challenge for market players.

Table of Content

1. Executive Summary | Optic Neuropathy Management Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Corticosteroids

        5.3.2. Antimetabolites

        5.3.3. Anticoagulants

        5.3.4. Serotonin and norepinephrine reuptake inhibitors

        5.3.5. Nonsteroidal Anti-Inflammatory Drugs

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Oral

        6.3.2. Injectable

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Pharmacies

        7.3.4. Drug Stores

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East & Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. United States

            9.2.1.2. Canada

        9.2.2. By Drug Class

        9.2.3. By Route of Administration

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Route of Administration

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Class

        10.2.3. By Route of Administration

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Route of Administration

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Class

        11.2.3. By Route of Administration

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Route of Administration

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Class

        12.2.3. By Route of Administration

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Route of Administration

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Class

        13.2.3. By Route of Administration

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By Route of Administration

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Class

        14.2.3. By Route of Administration

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Class

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Class

        15.2.3. By Route of Administration

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Class

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. U.S.

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Class

            16.1.2.2. By Route of Administration

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Class

            16.2.2.2. By Route of Administration

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Class

            16.3.2.2. By Route of Administration

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Class

            16.4.2.2. By Route of Administration

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Class

            16.5.2.2. By Route of Administration

            16.5.2.3. By Distribution Channel

    16.6. U.K.

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Class

            16.6.2.2. By Route of Administration

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Class

            16.7.2.2. By Route of Administration

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Class

            16.8.2.2. By Route of Administration

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Class

            16.9.2.2. By Route of Administration

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Class

            16.10.2.2. By Route of Administration

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Class

            16.11.2.2. By Route of Administration

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Class

            16.12.2.2. By Route of Administration

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Class

            16.13.2.2. By Route of Administration

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Class

            16.14.2.2. By Route of Administration

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Class

            16.15.2.2. By Route of Administration

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Class

            16.16.2.2. By Route of Administration

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Class

            16.17.2.2. By Route of Administration

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Class

            16.18.2.2. By Route of Administration

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Class

            16.19.2.2. By Route of Administration

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Class

            16.20.2.2. By Route of Administration

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Class

            16.21.2.2. By Route of Administration

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Class

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. AbbVie Inc.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Eli Lilly and Company

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. GSK Plc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Pfizer Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Teva Pharmaceutical Industries Ltd.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Bausch Health Companies Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. F. Hoffmann-La Roche AG

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Bayer AG

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Sanofi S.A.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Bristol-Myers Squibb Company

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Neurodegenerative Disease Market

May 2024

REP-GB-1052

250 pages

Healthcare

Ophthalmic Diagnostic Equipment Market

March 2024

REP-GB-771

347 pages

Healthcare

Optical Imaging Market

March 2024

REP-GB-402

333 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Optic Neuropathy Management Market

Schedule a Call